

FORM PTO-1449 (modified)		Atty. Dkt. No. 037003-0280609
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: GRILLO-LOPEZ
		Appn. No.: 09/840,872
		Filing Date: April 25, 2001
Date: January 12, 2006		Examiner: Gary B. Nickol
Page 1 of 1		Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FR						
GR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
HR						
IR						
JR						
KR						
LR						
MR						
NR						

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

OR	Anolik et al., "The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus," <i>Arthritis Rheum.</i> , 2003, 48:455-459.
PR	Cartron et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene," <i>Blood</i> , 2002, 99(3): 754-758.
QR	Clynes et al., "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets," <i>Nature Medicine</i> , 2000, 6(4): 443-446.
RR	Friese et al., "The innate immune response in the central nervous system and its role in glioma immune surveillance," <i>Onkologie</i> , 2004, 27(5):487-491.
SR	Rubenstein et al., "Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment," <i>Blood</i> , 2003, 101(2): 466-468.
TR	Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies," <i>Blood</i> , 1998, 91(5): 1644-1652.
UR	Shan et al., "Signaling events involved in anti-CD20-Induced apoptosis of malignant human B cells," <i>Cancer Immunol. Immunother.</i> , 2000, 48(12): 673-683 (abstract only).
VR	Treon et al., "Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia," <i>J. Clin. Oncol.</i> , 2005, 23(3): 474-481.

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.